176 related articles for article (PubMed ID: 25306892)
1. Ormeloxifene efficiently inhibits ovarian cancer growth.
Maher DM; Khan S; Nordquist JL; Ebeling MC; Bauer NA; Kopel L; Singh MM; Halaweish F; Bell MC; Jaggi M; Chauhan SC
Cancer Lett; 2015 Jan; 356(2 Pt B):606-12. PubMed ID: 25306892
[TBL] [Abstract][Full Text] [Related]
2. A triphenylethylene nonsteroidal SERM attenuates cervical cancer growth.
Chauhan N; Maher DM; Yallapu MM; B Hafeez B; Singh MM; Chauhan SC; Jaggi M
Sci Rep; 2019 Jul; 9(1):10917. PubMed ID: 31358785
[TBL] [Abstract][Full Text] [Related]
3. Ormeloxifene nanotherapy for cervical cancer treatment.
Chauhan N; Maher DM; Hafeez BB; Mandil H; Singh MM; Yallapu MM; Jaggi M; Chauhan SC
Int J Nanomedicine; 2019; 14():7107-7121. PubMed ID: 31564868
[TBL] [Abstract][Full Text] [Related]
4. Sulforaphane regulates apoptosis- and proliferation‑related signaling pathways and synergizes with cisplatin to suppress human ovarian cancer.
Kan SF; Wang J; Sun GX
Int J Mol Med; 2018 Nov; 42(5):2447-2458. PubMed ID: 30226534
[TBL] [Abstract][Full Text] [Related]
5. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
6. Ormeloxifene-induced unfolded protein response contributes to autophagy-associated apoptosis via disruption of Akt/mTOR and activation of JNK.
Bhattacharjee A; Hasanain M; Kathuria M; Singh A; Datta D; Sarkar J; Mitra K
Sci Rep; 2018 Feb; 8(1):2303. PubMed ID: 29396506
[TBL] [Abstract][Full Text] [Related]
7. The Novel IκB Kinase β Inhibitor, IMD-0560, Has Potent Therapeutic Efficacy in Ovarian Cancer Xenograft Model Mice.
Sawada I; Hashimoto K; Sawada K; Kinose Y; Nakamura K; Toda A; Nakatsuka E; Yoshimura A; Mabuchi S; Fujikawa T; Itai A; Kimura T
Int J Gynecol Cancer; 2016 May; 26(4):610-8. PubMed ID: 26905334
[TBL] [Abstract][Full Text] [Related]
8. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.
Selvendiran K; Ahmed S; Dayton A; Kuppusamy ML; Rivera BK; Kálai T; Hideg K; Kuppusamy P
Cancer Biol Ther; 2011 Nov; 12(9):837-45. PubMed ID: 21885917
[TBL] [Abstract][Full Text] [Related]
9. Chaetoglobosin K induces apoptosis and G2 cell cycle arrest through p53-dependent pathway in cisplatin-resistant ovarian cancer cells.
Li B; Gao Y; Rankin GO; Rojanasakul Y; Cutler SJ; Tu Y; Chen YC
Cancer Lett; 2015 Jan; 356(2 Pt B):418-33. PubMed ID: 25304379
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.
Chen XX; Xie FF; Zhu XJ; Lin F; Pan SS; Gong LH; Qiu JG; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Shi Z; Yan XJ
Oncotarget; 2015 Jun; 6(17):14926-39. PubMed ID: 25962959
[TBL] [Abstract][Full Text] [Related]
11. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.
Puvanenthiran S; Essapen S; Seddon AM; Modjtahedi H
Int J Oncol; 2016 Nov; 49(5):1825-1838. PubMed ID: 27599579
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer.
Brouwer-Visser J; Lee J; McCullagh K; Cossio MJ; Wang Y; Huang GS
PLoS One; 2014; 9(6):e100165. PubMed ID: 24932685
[TBL] [Abstract][Full Text] [Related]
13. Ormeloxifene Suppresses Prostate Tumor Growth and Metastatic Phenotypes via Inhibition of Oncogenic β-catenin Signaling and EMT Progression.
Hafeez BB; Ganju A; Sikander M; Kashyap VK; Hafeez ZB; Chauhan N; Malik S; Massey AE; Tripathi MK; Halaweish FT; Zafar N; Singh MM; Yallapu MM; Chauhan SC; Jaggi M
Mol Cancer Ther; 2017 Oct; 16(10):2267-2280. PubMed ID: 28615299
[TBL] [Abstract][Full Text] [Related]
14. Combination of Tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in vitro and in vivo.
Zhang Y; Wang C; Wang H; Wang K; Du Y; Zhang J
Cancer Lett; 2011 May; 304(1):21-32. PubMed ID: 21333438
[TBL] [Abstract][Full Text] [Related]
15. Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses.
Coughlin K; Anchoori R; Iizuka Y; Meints J; MacNeill L; Vogel RI; Orlowski RZ; Lee MK; Roden RB; Bazzaro M
Clin Cancer Res; 2014 Jun; 20(12):3174-86. PubMed ID: 24727327
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticle formulation of ormeloxifene for pancreatic cancer.
Khan S; Chauhan N; Yallapu MM; Ebeling MC; Balakrishna S; Ellis RT; Thompson PA; Balabathula P; Behrman SW; Zafar N; Singh MM; Halaweish FT; Jaggi M; Chauhan SC
Biomaterials; 2015; 53():731-43. PubMed ID: 25890768
[TBL] [Abstract][Full Text] [Related]
17. Icaritin induces ovarian cancer cell apoptosis through activation of p53 and inhibition of Akt/mTOR pathway.
Gao L; Chen M; Ouyang Y; Li R; Zhang X; Gao X; Lin S; Wang X
Life Sci; 2018 Jun; 202():188-194. PubMed ID: 29625193
[TBL] [Abstract][Full Text] [Related]
18. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells.
Sun X; Lou LG; Sui DH; Wu XH
Asian Pac J Cancer Prev; 2014; 15(22):9939-43. PubMed ID: 25520132
[TBL] [Abstract][Full Text] [Related]
19. Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells.
Kumar S; Bryant CS; Chamala S; Qazi A; Seward S; Pal J; Steffes CP; Weaver DW; Morris R; Malone JM; Shammas MA; Prasad M; Batchu RB
Mol Cancer; 2009 Apr; 8():26. PubMed ID: 19386116
[TBL] [Abstract][Full Text] [Related]
20. Valeriana jatamansi constituent IVHD-valtrate as a novel therapeutic agent to human ovarian cancer: in vitro and in vivo activities and mechanisms.
Li X; Chen T; Lin S; Zhao J; Chen P; Ba Q; Guo H; Liu Y; Li J; Chu R; Shan L; Zhang W; Wang H
Curr Cancer Drug Targets; 2013 May; 13(4):472-83. PubMed ID: 23597199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
